Optimal Surgical Approach for Early-Stage Breast Cancer in Chinese Patients Aged ≤ 40 Years: a Cohort Study

West China Hospital974 enrolled

Overview

The optimal surgical treatment option (BCS+RT versus MAST) for young patients with early-stage breast cancer remains debated. The present study aims to explore trends in surgical management and compare survival outcomes between BCS+RT and MAST in young patients with early-stage breast cancer, ultimately providing optimal treatment strategies for Asian populations.

This study is a unique addition to the current research on young women with early-stage breast cancer, aiming to compare the survival outcomes between BCS+RT and MAST, providing valuable insights into their effectiveness for this group of patients. This study enrolled patients at West China Hospital, Sichuan University. Kaplan-Meier analyses with the log-rank test were applied to compare the locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), breast cancer-specific survival (BCSS), and overall survival (OS). Cox multivariate hazard regression was employed to assess hazard ratios (HRs) between the two groups for survival outcomes.

Study Type

OBSERVATIONAL

Enrollment

974

Conditions

Breast Cancer

Interventions

MAST groupPROCEDURE

breast-conserving surgery plus adjuvant radiotherapyPROCEDURE

Patients with early-stage (stage I, stage II, T≤2), and having the willingness to receive BCS were treated with BCS. All patients with BCS received post-surgery radiotherapy. Radiotherapy was administrated with a prescribed dose of 40 Gy in 15 fractions with photons and a boost of 10-16 Gy in 5-8 fractions with electrons to the ipsilateral breast. If axillary lymph nodes were involved, a conventional fraction was delivered with a prescribed dose of 50 Gy in 25 fractions to the ipsilateral breast and draining lymph node regions.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients aged 18-40 years. * Pathological diagnosis of invasive breast cancer. * Undergoing Breast-Conserving Surgery (BCS) with Radiotherapy (RT) or Mastectomy (MAST). * Availability of detailed clinical information, including: Tumor (T) stage. Node (N) stage. Clinical stage. Hormone receptor status. Endocrine therapy details. Targeted therapy details. Exclusion Criteria: * Male patients. * Patients with distant metastatic disease. * Patients with bilateral breast cancer. * Patients not undergoing surgery. * Follow-up time of less than 1 month.

Outcomes

Primary Outcomes

Breast cancer-specific survival (BCSS)

Time frame: Jan 1, 2008 to 31 Dec, 2019

LRFS (Locoregional Recurrence-Free Survival)

Time frame: Jan 1, 2008 to 31 Dec, 2019

DMFS (Distant Metastasis-Free Survival)

Time frame: Jan 1, 2008 to 31 Dec, 2019

OS (Overall Survival)

Time frame: Jan 1, 2008 to 31 Dec, 2019

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.